Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

(2019) Kamal Chamoun et al.   Journal of Hematology & Oncology

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

(2018) Simona Soverini et al.   Molecular Cancer

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy

(2018) Massimiliano Bonifacio et al.   LEUKEMIA RESEARCH

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing

(2017) Christopher T. Chen et al.   Journal of Oncology Practice

OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY.

(2017) Mohamed Amine BEKADJA   Mediterranean Journal of Hematology and Infectious Diseases

Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study

(2016) Alen Ostojic et al.   Clinical Lymphoma Myeloma & Leukemia

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey

(2016) Aaron S. Kesselheim et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

(2016) William V. Padula et al.   JNCI-Journal of the National Cancer Institute

Generic oncology drugs: are they all safe?

(2016) Y Tony Yang et al.   LANCET ONCOLOGY

Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer

(2016) J Geissler et al.   LEUKEMIA

A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets

(2016) Rachna Arora et al.   Cancer Research and Treatment

Prevalence and Predictors of Generic Drug Skepticism Among Physicians

(2016) Aaron S. Kesselheim et al.   JAMA Internal Medicine

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

(2016) William V. Padula et al.   JNCI-Journal of the National Cancer Institute

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

(2015) Rena M. Conti et al.   ANNALS OF HEMATOLOGY

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

(2014) Ahmet Emre Eskazan et al.   BRITISH JOURNAL OF HAEMATOLOGY

The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia

(2014) Ahmet Emre Eskazan et al.   LEUKEMIA & LYMPHOMA

Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety

(2014) Domingo Saavedra et al.   LEUKEMIA & LYMPHOMA

Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back

(2014) Alaa Fadhil Alwan et al.   LEUKEMIA & LYMPHOMA

Clinical efficacy of generic imatinib

(2014) Mario L de Lemos et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase

(2010) Mervat Mattar   INTERNATIONAL JOURNAL OF HEMATOLOGY

Hematologic and Molecular Responses to Generic Imatinib in Patients With Chronic Myeloid Leukemia

(2010) Farnaz Razmkhah et al.   Labmedicine

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers

(2009) Susana Parrillo-Campiglia et al.   CLINICAL THERAPEUTICS